Regulatory Scientist, Rare Diseases Program, Office of New Drugs, CDER, FDA
Larry Bauer is a Regulatory Scientist in the Center for Drug Evaluation and Research, Office of New Drugs Immediate Office (CDER, OND IO) in the Rare Diseases Program. He provides regulatory expertise internally and externally regarding FDA laws, regulations, guidances and policies...
Read More →JJ
Principal, Drug and Biological Products, Greenleaf Health
Dr. John Jenkins is Principal, Drug and Biological Products at Greenleaf Health. Prior to joining Greeleaf, Dr. Jenkins was Director of the Office of New Drugs at FDA’s Center for Drug Evaluation and Research from 2002 to 2017. Dr. Jenkins received his M.D. degree from the University...
Read More → 
Vice President and Head, Regulatory Policy, North American Regulatory Affairs, Bayer
Kim Quaintance-Lunn serves as the Vice President and Head, NA Regulatory Policy at Bayer. She works with colleagues to analyze regulatory policy and advocate for changes in the regulatory environment, serves on global and US Regulatory Leadership teams, and assists in the development...
Read More →AR
Head, Global Regulatory Science and Policy, NA, Sanofi
Andrew Robertson is the Head of Regulatory Science and Policy NA at Sanofi, where he heads up regulatory policy initiatives in the US and Canada. Andrew has more than 14 years of collective experience working in life sciences, policy and law, and has authored multiple peer-reviewed...
Read More → 
